March 11, 2024. The Court in the Acadia Pharmaceuticals securities matter (Southern District of California) certified a class of common stock investors. Plaintiffs allege that Acadia misled the market about the prospects of FDA approval for the company’s dementia-related psychosis treatment pimavanserin. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports and testimony on market efficiency.



Read more on this case at Law360.